These 4 Measures Indicate That Bristol-Myers Squibb (NYSE:BMY) Is Using Debt Reasonably Well
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Segal Trials Plays Key Role in FDA Approval of COBENFY, A New Era in Schizophrenia Treatment
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $42, Maintains Underweight Rating
Bristol-Myers Squibb Says FDA Approves Perioperative Treatment of Neoadjuvant Opdivo in NSCLC
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo (Nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb Options Spot-On: On October 3rd, 367.35K Contracts Were Traded, With 802.8K Open Interest
Express News | FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable Non-Small Cell Lung Cancer
Daily short sale tracking: Ambev SA's short volume increased by 8 million, with a short sale ratio of 19%
U.S. Tweaks 2025 Medicare Price Negotiation Process
Bristol-Myers Squibb To Go Ex-Dividend On October 4th, 2024 With 0.6 USD Dividend Per Share
Bristol-Myers Squibb (BMY.US) collaborates with Prime Medicine (PRME.US) to develop innovative cell therapy.
Prime Medicine will receive an upfront payment of $55 million and $55 million in private equity, and is eligible for over $3.5 billion in milestone payments.
Bristol-Myers Squibb Options Spot-On: On October 2nd, 91,629 Contracts Were Traded, With 795.1K Open Interest
Bristol-Myers Tops Growth Chart Among S&P 500 Healthcare Stocks in Q3
This Is What Whales Are Betting On Bristol-Myers Squibb
IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO
Bristol-Myers Squibb Company (BMY) Is Driving Growth Through Strategic Acquisitions
Hold Rating on Bristol-Myers Squibb Amid Market Challenges and Strategic Execution Risks
US Federal Judge Dismisses $6.4 Billion Suit Against Bristol Myers Squibb
Sector Update: Health Care Stocks Steady Premarket Monday